Reshetnyak Yana K, Andreev Oleg A, Engelman Donald M
Physics Department, University of Rhode Island, Kingston, RI, United States.
Molecular Biophysics and Biochemistry Department, Yale, New Haven, CT, United States.
Front Pharmacol. 2024 Mar 13;15:1355893. doi: 10.3389/fphar.2024.1355893. eCollection 2024.
The family of pH (Low) Insertion Peptides (pHLIP) comprises a tumor-agnostic technology that uses the low pH (or high acidity) at the surfaces of cells within the tumor microenvironment (TME) as a targeted biomarker. pHLIPs can be used for extracellular and intracellular delivery of a variety of imaging and therapeutic payloads. Unlike therapeutic delivery targeted to specific receptors on the surfaces of particular cells, pHLIP targets cancer, stromal and some immune cells all at once. Since the TME exhibits complex cellular crosstalk interactions, simultaneous targeting and delivery to different cell types leads to a significant synergistic effect for many agents. pHLIPs can also be positioned on the surfaces of various nanoparticles (NPs) for the targeted intracellular delivery of encapsulated payloads. The pHLIP technology is currently advancing in pre-clinical and clinical applications for tumor imaging and treatment.
pH(低)插入肽(pHLIP)家族包含一种不依赖肿瘤类型的技术,该技术利用肿瘤微环境(TME)中细胞表面的低pH值(或高酸度)作为靶向生物标志物。pHLIP可用于多种成像和治疗载荷的细胞外和细胞内递送。与靶向特定细胞表面特定受体的治疗递送不同,pHLIP可同时靶向癌细胞、基质细胞和一些免疫细胞。由于TME表现出复杂的细胞间串扰相互作用,同时靶向并递送至不同细胞类型会对许多药物产生显著的协同效应。pHLIP还可定位在各种纳米颗粒(NP)表面,用于封装载荷的靶向细胞内递送。目前,pHLIP技术在肿瘤成像和治疗的临床前和临床应用方面正在取得进展。